Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AnGes MG Begins PIII Study on HGF Gene Therapy Drug
December 15, 2003
- Teikoku Hormone: Sales, Profits Declines
December 15, 2003
- Osaka Univ. Venture iCAT to Develop Implant Treatment System
December 15, 2003
- ON THE MOVW
December 15, 2003
- Dr Shirakawa Wins Baelz Prize for 2003
December 15, 2003
- Rohto: Added-value Products, Overseas Growth Boost Sales
December 15, 2003
- Press Seminar
December 15, 2003
- NHI Price Listing Approved for 11 Drugs Including Pediatric Protopic Ointment, BI・Sifrol
December 15, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
December 15, 2003
- New Options Available in Cancer Pain Treatment: Janssen, Kyowa Hakko Seminar
December 15, 2003
- Wakamoto: Cost-cutting Boosts Profits
December 15, 2003
- BUSINESS NEWS IN BRIEF
December 15, 2003
- 2nd Edition of Int'l Headache Classification Previewed: Pfizer Seminar
December 15, 2003
- Basic Policy for Next NHI Pricing System Reform Presented
December 15, 2003
- NEW PRODUCTS
December 15, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 15, 2003
- Price Discrepancy Rate Marks 6.3%: Price Survey
December 15, 2003
- Videophone-based Drug Sales to Be Approved
December 15, 2003
- MEDICAL DEVICE NEWS IN BRIEF
December 15, 2003
- Drug Price Revision Rate Next April to Be Lower than Previous 6.3%
December 15, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…